Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Want to see NMRA full AI Analyst Report?
NMRA Stock Chart & Stats
$2.15
-$0.22(-8.53%)
At close: 4:00 PM EST
$2.15
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.72 - $3.65
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$329.81M
Enterprise Value$196.11M
Total Cash (Recent Filing)$147.07M
Total Debt (Recent Filing)$410.00K
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding185,284,240
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-39.16
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$7.00Price Target Upside225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt reduces financial fragility and preserves strategic optionality. For a pre-commercial biotech, minimal leverage lowers near-term default risk and gives management flexibility to prioritize R&D, partnerships or selective financing rather than servicing large interest burdens.
Refocused Clinical Portfolio With Defined MilestonesFollowing the navacaprant discontinuation, management narrowed focus to three programs with upcoming clinical/toxicology milestones. Concentrated programs with defined near-term catalysts create clearer development priorities and potential value-inflection points over the next 6–12 months.
Board Continuity And Governance OversightRe-election of directors and auditor ratification signal governance continuity and stable oversight during restructuring. Steady board composition supports orderly execution of cost saves, program prioritization and capital strategy, reducing execution risk amid pipeline changes.
Bears Say
Late-stage Program Failure And DiscontinuationLoss of a Phase 3 asset removes the company’s most advanced value driver and materially raises execution risk. The setback reduces near-term clinical upside, lengthens the path to commercialization and increases dependency on earlier-stage programs to generate future value.
Persistent Negative Cash Flow And Heavy BurnSustained negative operating and free cash flow imply ongoing financing needs; this structurally increases dilution risk and constrains discretionary investment. Continuous burn necessitates access to capital or partnerships, pressuring long-term R&D timelines and strategic flexibility.
Pre-commercial Profile, No Revenue And Shrinking Equity CushionAbsence of commercial revenue means company value hinges on binary clinical outcomes and external financing. Ongoing losses have eroded equity, reducing the firm’s buffer for adverse events and amplifying the long-term risk of dilution or forced strategic transactions if milestones slip.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.71 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $329.81M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 57 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.016.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 185,284,240 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went down -16.738%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (225.58% Upside)
$7.00 (225.58% Upside)
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-181.70%
Trailing 12-Months
Asset Growth
-40.07%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$7.00
▲(225.58% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
59.25% Insiders
3.07% Mutual Funds
22.74% Other Institutional Investors
11.92% Public Companies and
Individual Investors